Compare ASH & IDYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ASH | IDYA |
|---|---|---|
| Founded | 1924 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Specialty Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.2B | 3.6B |
| IPO Year | 2016 | 2019 |
| Metric | ASH | IDYA |
|---|---|---|
| Price | $71.07 | $33.83 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 16 |
| Target Price | ★ $79.91 | $52.29 |
| AVG Volume (30 Days) | 546.5K | ★ 774.5K |
| Earning Date | 11-03-2026 | 11-03-2026 |
| Dividend Yield | ★ 2.36% | N/A |
| EPS Growth | N/A | ★ 61.90 |
| EPS | ★ 0.43 | N/A |
| Revenue | ★ $1,824,000,000.00 | $218,710,000.00 |
| Revenue This Year | $2.21 | N/A |
| Revenue Next Year | $3.54 | $189.87 |
| P/E Ratio | $165.33 | ★ N/A |
| Revenue Growth | N/A | ★ 3024.43 |
| 52 Week Low | $47.12 | $26.81 |
| 52 Week High | $78.25 | $42.68 |
| Indicator | ASH | IDYA |
|---|---|---|
| Relative Strength Index (RSI) | 54.59 | 35.65 |
| Support Level | $66.79 | $29.74 |
| Resistance Level | $75.51 | $35.14 |
| Average True Range (ATR) | 1.54 | 1.29 |
| MACD | 0.29 | -0.38 |
| Stochastic Oscillator | 74.09 | 17.84 |
Ashland Inc. is a specialty materials company serving markets including pharmaceuticals, personal care, food and beverages, coatings, construction, energy, and electronics. It operates through four segments: Life Sciences, Personal Care, Specialty Additives, and Intermediates. Life Sciences contributes the highest revenue, offering functional additives for pharmaceutical and nutrition applications. Personal Care provides ingredients for skin, hair, oral care, and household products, while Specialty Additives supplies performance-enhancing additives for coatings and. Intermediates produce BDO and related derivatives used in polymers, electronics, agriculture, and pharmaceutical applications. The company generates sales across North America, Europe, Asia Pacific, Latin America, and regions.
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275 (Werner Helicase), IDE161 (PARG), and IDE705 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.